AUTHORS
J Erin Wiedmeier-Nutor, MD,MPH, Surendra Dasari, Associate Professor2, Daniel Bihnam, MS3, Karl Franke, PhD, MS4, Juana Figueroa Aguirre, MD5, Mariano Arribas6, Laura Bruins7, Gregory Ahmann, BS8, Shaji Kumar, MD9, P. Leif Bergsagel, MD10, Rafael Fonseca, MD11, Esteban Braggio, PhD12
AFFILIATIONS
1 Mayo Clinic, Phoenix, Arizona, United States
2 Mayo Clinic, Rochester, Arizona, United States
3 Mayo Clinic, Phoenix, Arizona, United States
4 Mayo Clinic, Rochester, Arizona, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Mayo Clinic, Phoenix, Arizona, United States
9 Mayo Clinic, Rochester, Arizona, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States
ABSTRACT
Introduction: Advanced stage multiple myeloma (Adv-MM) is characterized by genomic complexity, therapy-driven genetic selection, and multidrug resistance. In this study, we characterized the molecular landscape of a cohort of Adv-MM by integrating genomic, transcriptomic, and epigenetic analyses and compared it with a cohort of newly diagnosed (ND) cases to identify molecular biomarkers of aggressive disease.
Methods: CD138? bone marrow plasma cells from ND MM (n=98) and Adv-MM patients (n=65, sample collection within 6 months of death) were analyzed by WES and RNAseq under IRB-approved protocol. DNA methylation profiling was performed on a subset of ND (n=30) and Adv-MM (n=30) samples using the Illumina Infinium MethylationEPIC v2.0 array. Plasma cell-free DNA (cfDNA) from a subset (ND, n=3; Adv-MM, n=3) underwent whole-genome enzymatic methyl sequencing (EM-seq). Clinical characteristics and survival were compared using standard statistical methods.
Results: Adv-MM revealed a higher prevalence of high risk cytogenetics, t(11;14), gain 1q, and TP53 alterations (52.3%, p < 0.01), including multi-hit events (p = 5.6 x 10-5) compared to ND. Adv-MM exhibited significantly more copy number gains involving CKS1B, PARP1, and MYC, and losses of CYLD, FAM46C, TET2, NCOR1, CDKN1B, ETV6, CDKN2A, and IKZF3. Expression analysis identified enrichment of proliferation and DNA damage response (DDR) genes, including high expression of RAD51, CHEK1, BRCA1, and PARP1, together with CKS1B, whereas FAM46C was downregulated in Adv-MM. Among DDR genes, CHEK1 expression was associated with accelerated progression in Adv-MM after adjustment for MM risk (HR = 1.46, 95% CI 1.08-1.98, p = 0.015). Spearman correlation analysis demonstrated strong positive correlations between DDR gene expression and proliferation index in both ND and Adv-MM (ρ = 0.917), suggesting that highly proliferative myeloma cells experience increased replication-associated stress and upregulate DDR pathways.
Cancer-testis antigen genes (CTAGs) were broadly overexpressed in Adv-MM compared to ND. CTAG single-sample gene set scoring (singscore) was significantly higher in Adv-MM compared with ND (p = 1.09 x 10-8). Patients in the highest quartile of CTAG singscores had inferior overall survival compared with those in the lowest quartile in ND after adjustment for MM risk (HR = 3.80, 95% CI 1.20–12.06, p = 0.023), whereas CTAG singscores were not associated with time to advanced disease progression in the Adv-MM cohort (p = 0.66).
Genome-wide DNA methylation analysis demonstrated widespread DNA hypomethylation in Adv-MM, including promoter hypomethylation of CTAGs. We also found that Adv-MM demonstrated significantly higher epigenetic age scores as measured by the Horvath clock compared to ND. Other genes significantly overexpressed in Adv-MM compared with ND and associated with transcriptional start site DNA hypomethylation included TLR4, FGFR3, CHEK1, and CDK2.
Cox proportional hazards and quasi-binomial regression identified 89 CpG sites associated with shorter time to progression in the Adv-MM group (time from MM diagnosis to sample collection, p <0.001). We applied the same analysis to the ND cohort, however, the limited number of progression events precluded identification of CpG sites that reached statistical significance.
We evaluated concordance of BM DNA methylation profiles with cfDNA methylation profiles. cfDNA also revealed global hypomethylation in Adv-MM compared to ND. A total of 86.6% of the CpGs profiled in the BM by the EPIC array were also profiled in the cfDNA by EM-seq. There was substantial overlap between differentially methylated CpGs in BM and cfDNA of 41.4% (85,773 out of 207,111 in BM). 769 were in potential promoter regions of genes which were differentially regulated in concordance with the change in methylation in the BM, and 23 of these were CTAGs.
Conclusion: Our analyses of Adv-MM identified frequent TP53 alterations, 1q gain, enrichment of DDR and proliferative pathways, and overexpression of CTAGs. We also identified global DNA hypomethylation, increased epigenetic age scores, and the identification of an 89-CpG DNA methylation signature associated with shorter time to progression, suggesting DNA methylation may serve as a prognostic biomarker. Methylation changes in the BM corresponded to those in cfDNA, highlighting the potential of cfDNA methylation profiling as a minimally invasive biomarker for disease monitoring and progression in MM.
DISCLOSURES
J Erin Wiedmeier-Nutor, MD,MPH: No relevant conflicts of interest to declare.